MX354506B - Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa. - Google Patents
Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa.Info
- Publication number
- MX354506B MX354506B MX2013006462A MX2013006462A MX354506B MX 354506 B MX354506 B MX 354506B MX 2013006462 A MX2013006462 A MX 2013006462A MX 2013006462 A MX2013006462 A MX 2013006462A MX 354506 B MX354506 B MX 354506B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- substituted pyrazolopyrimidines
- glucocerebrosidase
- activators
- methods
- Prior art date
Links
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004547 Glucosylceramidase Human genes 0.000 title 1
- 108010017544 Glucosylceramidase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42094610P | 2010-12-08 | 2010-12-08 | |
| PCT/US2011/063928 WO2012078855A1 (en) | 2010-12-08 | 2011-12-08 | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013006462A MX2013006462A (es) | 2013-10-01 |
| MX354506B true MX354506B (es) | 2018-01-16 |
Family
ID=45498099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013006462A MX354506B (es) | 2010-12-08 | 2011-12-08 | Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa. |
| MX2018000385A MX385600B (es) | 2010-12-08 | 2011-12-08 | Pirazolopirimidinas sustituidas como activadores de la glucocerebrosidasa. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000385A MX385600B (es) | 2010-12-08 | 2011-12-08 | Pirazolopirimidinas sustituidas como activadores de la glucocerebrosidasa. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9353117B2 (enExample) |
| EP (2) | EP2649075B1 (enExample) |
| JP (1) | JP6154746B2 (enExample) |
| KR (1) | KR101931224B1 (enExample) |
| CN (1) | CN103534255B (enExample) |
| AU (1) | AU2011338377B2 (enExample) |
| BR (1) | BR112013014242B1 (enExample) |
| CA (1) | CA2820362C (enExample) |
| CY (1) | CY1125186T1 (enExample) |
| DK (2) | DK2649075T3 (enExample) |
| ES (2) | ES2681218T3 (enExample) |
| HR (1) | HRP20220512T1 (enExample) |
| HU (1) | HUE038635T2 (enExample) |
| IL (2) | IL226767B (enExample) |
| LT (1) | LT3366688T (enExample) |
| MX (2) | MX354506B (enExample) |
| PL (2) | PL2649075T3 (enExample) |
| PT (2) | PT3366688T (enExample) |
| RS (1) | RS63320B1 (enExample) |
| RU (1) | RU2603637C2 (enExample) |
| SI (2) | SI3366688T1 (enExample) |
| TR (1) | TR201810523T4 (enExample) |
| WO (1) | WO2012078855A1 (enExample) |
| ZA (1) | ZA201304215B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3366688T (pt) * | 2010-12-08 | 2022-05-11 | Us Health | Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase |
| CN103764166B (zh) * | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用 |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| BR112014009531A8 (pt) * | 2011-10-20 | 2018-01-16 | Glaxosmithkline Llc | aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201902074UA (en) | 2013-10-04 | 2019-04-29 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| AU2015277212B2 (en) | 2014-06-17 | 2020-07-02 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2015342021B2 (en) | 2014-11-03 | 2020-02-27 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
| EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| PT3215511T (pt) * | 2014-11-06 | 2024-05-22 | Bial R&D Invest S A | Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos |
| CN108290894A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20190092789A1 (en) * | 2015-09-04 | 2019-03-28 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| WO2017040879A1 (en) * | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| WO2017161137A1 (en) * | 2016-03-16 | 2017-09-21 | Lysosomal Therapeutics Inc. | Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| EP3440080A4 (en) * | 2016-04-06 | 2020-01-22 | Lysosomal Therapeutics Inc. | PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| WO2017176962A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3452480A4 (en) * | 2016-05-05 | 2019-11-06 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| JP7164774B2 (ja) * | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP7059268B2 (ja) * | 2016-11-02 | 2022-04-25 | エフ．ホフマン－ラ ロシュ アーゲー | ＩＲＡＫ４モデュレーターとしてのピラゾロ［１，５ａ］ピリミジン誘導体 |
| DK3658557T3 (da) * | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| CA3071534A1 (en) | 2017-08-02 | 2019-02-07 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
| US11247987B2 (en) | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| WO2019151269A1 (ja) | 2018-01-31 | 2019-08-08 | 武田薬品工業株式会社 | 複素環化合物 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| US10882865B2 (en) | 2018-08-31 | 2021-01-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
| US11891400B2 (en) | 2018-09-10 | 2024-02-06 | Eli Lilly And Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| CN113271940A (zh) * | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| MX2022002152A (es) * | 2019-08-21 | 2022-05-18 | Scripps Research Inst | Agonistas biciclicos del estimulador de genes de interferon sting. |
| US20220380314A1 (en) | 2019-09-17 | 2022-12-01 | Bial - R&D Investments, S.A. | Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders |
| CA3150700A1 (en) | 2019-09-17 | 2021-03-25 | Renato T. Skerlj | IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP2022548747A (ja) | 2019-09-17 | 2022-11-21 | バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ | 酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用 |
| MX2022006059A (es) * | 2019-11-25 | 2022-09-12 | Gain Therapeutics Sa | Compuestos de arilo y heteroarilo, y usos terapeuticos de los mismos en condiciones asociadas con la alteracion de la actividad de galactocerebrosidasa. |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037373A2 (en) | 2002-10-21 | 2004-05-06 | The Scripps Research Institute | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| WO2004089471A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| US20050137223A1 (en) | 2003-11-12 | 2005-06-23 | Amicus Therapeutics, Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| CA2507348C (en) | 2004-05-13 | 2013-07-16 | The Hospital For Sick Children | Real time methylumbelliferone-based assay |
| US8318724B2 (en) * | 2004-05-14 | 2012-11-27 | The Cleveland Clinic Foundation | Small molecule inhibitors of MRP1 and other multidrug transporters |
| AU2005254657B2 (en) | 2004-06-21 | 2011-03-17 | F. Hoffmann-La Roche Ag | Pyrrazolo-pyrimidine derivatives |
| DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| AU2006251989B2 (en) | 2005-05-20 | 2010-05-27 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| US20070155737A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| ATE537169T1 (de) * | 2005-08-15 | 2011-12-15 | Hoffmann La Roche | Piperidin- und piperazinderivate als p2x3- antagonisten |
| ATE517874T1 (de) * | 2005-10-21 | 2011-08-15 | Exelixis Inc | Pyrimidinone als modulatoren von caseinkinase ii (ck2) |
| KR101071438B1 (ko) * | 2005-10-21 | 2011-10-10 | 미쓰비시 타나베 파마 코퍼레이션 | 카나비노이드 수용체 길항제로서의피라졸로[1,5-ａ]피리미딘 화합물 |
| WO2008054947A2 (en) | 2006-10-02 | 2008-05-08 | The Brigham And Women's Hospital, Inc. | Structure of acid beta-glucosidase and methods for identifying therapeutic agents |
| US20090275586A1 (en) | 2006-10-06 | 2009-11-05 | Kalypsys, Inc. | Heterocyclic inhibitors of pde4 |
| CA2670083A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| JP5586453B2 (ja) | 2007-04-13 | 2014-09-10 | アミカス セラピューティックス インコーポレイテッド | 特異的薬理シャペロンによるゴーシェ病の治療および代理マーカーを用いた治療の監視 |
| WO2008134035A1 (en) | 2007-04-27 | 2008-11-06 | Panacos Pharmaceuticals, Inc. | Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives |
| PL2154969T3 (pl) | 2007-05-16 | 2016-04-29 | Brigham & Womens Hospital Inc | Leczenie synukleinopatii |
| WO2008154207A1 (en) | 2007-06-08 | 2008-12-18 | The Burnham Institute For Medical Research | Methods and compounds for regulating apoptosis |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN104530052A (zh) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
| EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | HEPARAN SULFATE INHIBITORS |
| WO2010086040A1 (en) * | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| PT3366688T (pt) | 2010-12-08 | 2022-05-11 | Us Health | Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase |
| PT3215511T (pt) * | 2014-11-06 | 2024-05-22 | Bial R&D Invest S A | Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos |
-
2011
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
-
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
-
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
-
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
-
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX354506B (es) | Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa. | |
| MX2012004551A (es) | Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal. | |
| NZ706296A (en) | Glucosylceramide synthase inhibitors | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| WO2012129084A3 (en) | Glucosylceramide synthase inhibitors | |
| WO2012104007A3 (de) | 7-azaindolderivate | |
| NZ597517A (en) | 5-fluoropyrimidinone derivatives | |
| MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| IN2012DN03883A (enExample) | ||
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX2013004004A (es) | Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2). | |
| MX336022B (es) | Activadores de pkm2 bicíclicos. | |
| NZ597483A (en) | N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives | |
| NZ597570A (en) | N1-acyl-5-fluoropyrimidinone derivatives | |
| WO2011130537A3 (en) | Pharmaceutical compositions and methods for digesting atherosclerotic plaques | |
| WO2009095261A3 (en) | Vaccine compositions | |
| WO2012017321A3 (en) | Treatment for dyslipidemia | |
| MX2014001862A (es) | 5-cicloalquil-o 5-heterociclil-nicotinamidas. | |
| MX2015004312A (es) | Formulacion de aroma y fragancia (i). | |
| SG178967A1 (en) | Antimicrobial compositions and products | |
| NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases | |
| CY1117258T1 (el) | Νεες συνθεσεις για την προληψη και/ή την θεραπευτικη αγωγη διαταραχων λυσοσωμικης αποθηκευση | |
| WO2012083408A8 (pt) | Composições farmacêuticas antimaláricas contendo derivados de diterpenos caurânicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |